Patents by Inventor C. Frank Bennett

C. Frank Bennett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SELECTIVE REDUCTION OF ALLELIC VARIANTS
    Publication number: 20150292015
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
    Type: Application
    Filed: March 3, 2015
    Publication date: October 15, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
  • MODULATION OF CD40 EXPRESSION
    Publication number: 20150291960
    Abstract: Disclosed herein are antisense compounds and methods for decreasing CD40. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to CD40 include hyperproliferative disorders, graft versus host disease (GVHD), graft rejection, asthma, airway hyperresponsiveness, chronic obstructive pulmonary disease (COPD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), and certain forms of arthritis.
    Type: Application
    Filed: November 17, 2014
    Publication date: October 15, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Lex M. Cowsert, Susan M. Freier
  • Chimeric oligomeric compounds for modulation of splicing
    Patent number: 9157081
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of a selected target mRNA. Further provided are uses of the disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Methods of enhancing cellular uptake, modulating tissue distribution and enhancing pharmacological activity of RNase H-independent antisense oligonucleotides are also provided.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: October 13, 2015
    Assignees: Isis Pharmaceuticals, Inc., Sarepta Therapeutics
    Inventors: C. Frank Bennett, Nicholas M. Dean, Ryszard M. Kole, Casey C. Kopczynski
  • Targeting microRNAs for the treatment of liver cancer
    Patent number: 9150857
    Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: October 6, 2015
    Assignees: Regulus Therapeutics, Rosetta Genomics, Ltd.
    Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
  • METHODS FOR MODULATING TAU EXPRESSION FOR REDUCING SEIZURE AND MODIFYING A NEURODEGENERATIVE SYNDROME
    Publication number: 20150275205
    Abstract: Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 1, 2015
    Inventors: Timothy M. Miller, Sarah Devos, C. Frank Bennett, Frank Rigo
  • METHODS FOR MODULATING C9ORF72 EXPRESSION
    Publication number: 20150267197
    Abstract: Disclosed herein are methods for reducing expression of C90RF72 mRNA and protein in an animal with C90RF72 specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C90RF72 specific inhibitors include antisense compounds. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration C90RF72 specific inhibitors include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticalbasal degeneration syndrome (CBD), atypical Parkinsonian syndrome, and olivopontocerellar degeneration (OPCD).
    Type: Application
    Filed: October 15, 2013
    Publication date: September 24, 2015
    Applicants: ISIS PHARMACEUTICALS, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: C. Frank Bennett, Susan M. Freier, Frank Rigo, Don W. Cleveland, Clotilde Lagier-Tourenne, John M. Ravits, Michael W. Baughn
  • Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
    Patent number: 9139832
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: September 22, 2015
    Assignee: Regulus Therapeutics Inc.
    Inventors: Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Eric E. Swayze, Ravi Jain, Balkrishen Bhat
  • COMPOSITIONS FOR MODULATING C9ORF72 EXPRESSION
    Publication number: 20150259679
    Abstract: Disclosed herein are compositions and methods for reducing expression of C90RF72 mRNA and protein in an animal with C90RF72 specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C90RF72 specific inhibitors include antisense compounds. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration C90RF72 specific inhibitors include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticalbasal degeneration syndrome (CBD), atypical Parkinsonian syndrome, and olivopontocerellar degeneration (OPCD).
    Type: Application
    Filed: October 15, 2013
    Publication date: September 17, 2015
    Inventors: C. Frank Bennett, Susan M. Freier, Frank Rigo, Eric E. Swayze
  • Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
    Patent number: 9096851
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: August 4, 2015
    Assignees: Excaliard Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Frier
  • ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
    Publication number: 20150167008
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
    Type: Application
    Filed: February 24, 2015
    Publication date: June 18, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Kenneth W. Dobie
  • Compositions and their uses directed to huntingtin
    Patent number: 9057066
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: June 16, 2015
    Assignees: Isis Pharmaceuticals, Inc., CHDI Foundation Inc.
    Inventors: Gene Hung, Janet M. Leeds, C. Frank Bennett, Susan M. Freier
  • MODULATION OF HUNTINGTIN EXPRESSION
    Publication number: 20150159155
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: October 30, 2014
    Publication date: June 11, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Selective reduction of allelic variants
    Patent number: 9006198
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: April 14, 2015
    Assignees: Isis Pharmaceuticals, Inc., The University of British Columbia
    Inventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
  • Compounds and methods for improving cellular uptake of oligomeric compounds
    Patent number: 8999951
    Abstract: The present invention provides method of optimizing the efficacy and potency of antisense drugs. In certain embodiments, the invention provides assays useful for determining favorable oligonucleotide characteristics and excipients for improved cellular uptake.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: April 7, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Erich Koller, C. Frank Bennett
  • OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS
    Publication number: 20150094461
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Application
    Filed: December 15, 2014
    Publication date: April 2, 2015
    Inventors: C. Frank Bennett, Susan M. Freier, Richard H. Griffey
  • Antisense modulation of superoxide dismutase 1, soluble expression
    Patent number: 8993529
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: March 31, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie
  • Compositions and methods for modulation of SMN2 splicing in a subject
    Patent number: 8980853
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: March 17, 2015
    Assignees: Isis Pharmaceuticals, Inc., Cold Spring Harbor Laboratory
    Inventors: C. Frank Bennett, Gene Hung, Frank Rigo, Adrian R. Krainer, Yimin Hua, Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng, Katherine W. Klinger
  • Selective reduction of allelic variants
    Patent number: 8957040
    Abstract: Disclosed herein are antisense compounds and methods for selectively of reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative, such as Huntington's Disease (HD).
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: February 17, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Sarah Greenlee, Eric E. Swayze
  • Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
    Patent number: 8946179
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: February 3, 2015
    Assignee: Regulus Therapeutics, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Richard H. Griffey
  • Method for reducing scarring during wound healing using antisense compounds directed to CTGF
    Patent number: 8946172
    Abstract: This invention provides a method for reducing hypertropic scarring resulting from dermal wound healing in a subject in need which comprises administering to the subject an antisense oligonucleotide which inhibits expression of connective tissue growth factor (CTGF) in an amount effective to inhibit expression of CTGF and thereby reduce hypertrophic scarring.
    Type: Grant
    Filed: August 26, 2009
    Date of Patent: February 3, 2015
    Assignees: Excaliard Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., Northwestern University
    Inventors: Thomas A. Mustoe, Nicholas M. Dean, Mark Sisco, Zol Kryger, C. Frank Bennett